Top-News
Freitag,
17.02.2017 13:05
von
PR Newswire
| Aufrufe: 132
SHIRE PLC - Director/PDMR Shareholding
Ein Labormitarbeiter bei der Arbeit (Symbolbild).
© Totojang / iStock / Getty Images Plus / Getty Images
PR Newswire
London, February 17
Director/PDMR Shareholding
February 17, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”)
Notification of transactions by person discharging managerial responsibilities
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | ||
| a) | Name | Kim Stratton | |
| 2. | Reason for the notification | ||
| a) | Position / status | Head of International Commercial – PDMR | |
| b) | Initial notification / amendment | Amendment to prior notification to include the automatic disposal of Ordinary Shares, as omitted from the initial notification due to a transcription error, related to the automatic exercise of an option as detailed in the initial notification. | |
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Shire plc | |
| b) | LEI | 54930005LQRLI2UXRQ59 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”) | |
| Identification code | ISIN: JE00B2QKY057 | ||
| b) | Nature of the transaction | Automatic exercise of option over notional Ordinary Shares granted under the Shire Global Employee Stock Purchase Plan on November 1, 2015, and consequent receipt of Ordinary Shares. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £40.70 | 244 | ||
| d) | Aggregated information | N/A (single transaction) | |
| e) | Date of the transaction | October 31, 2016 | |
| f) | Place of the transaction | N/A | |
| 5. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”) | |
| Identification code | ISIN: JE00B2QKY057 | ||
| b) | Nature of the transaction | Automatic disposal of Ordinary Shares related to the automatic option exercise referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the option exercise. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £46.07 | 9 | ||
| d) | Aggregated information | N/A (single transaction) | |
| e) | Date of the transaction | October 31, 2016 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Ian Karp | ikarp@shire.com | +1 781 482 9018 |
| Robert Coates | rcoates@shire.com | +44 1256 894874 |
| Media | ||
| Lisa Adler | lisa.adler@shire.com | +1 617 588 8607 |
| Debbi Ford | debbi.ford@shire.com | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
Werbung
Mehr Nachrichten zur Shire ADR Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
